AbbVie Inc. (NYSE: ABBV) saw its shares pull back on Thursday after it reported less than favorable midstage results for its relapsed/refractory small cell lung cancer (SCLC) trial. Specifically, the firm reported Phase 2 data evaluating rovalpituzumab tesirine (Rova-T).
Unfortunately, the firm has decided that it will not pursue accelerated approval of Rova-T in third-line SCLC, based on magnitude of effect across multiple parameters in this single-arm study. This came after consulting with the U.S. Food and Drug Administration.
Note that ongoing Phase 3 studies, MERU and TAHOE, will continue to investigate Rova-T in first-line and second-line SCLC.
In the study, the most common treatment-emergent adverse events were fatigue (38%), photosensitivity reaction (36%), pleural effusion (32%), edema peripheral (31%), decreased appetite (30%), nausea (26%), dyspnea (25%), thrombocytopenia (25%), constipation (22%), vomiting (17%), anemia (17%), hypoalbuminemia (16%), and cough (16%). Grade three and higher severe toxicities ≥5% were thrombocytopenia (11%), photosensitivity reaction (7%) and pleural effusion (5%).
Mike Severino, M.D., executive vice president of research and development and chief scientific officer of AbbVie, commented:
We continue to believe Rova-T has potential for patients with small cell lung cancer and other DLL3-expressing cancers. Although the results from the study were not what we hoped for, we look forward to receiving data from the ongoing Phase 3 studies in the first- and second-line settings and remain committed to developing Rova-T for the treatment of patients with small cell lung cancer.
Shares of AbbVie were last seen down 11% at $99.59 on Thursday, with a consensus analyst price target of $125.90 and a 52-week range of $63.12 to $125.86.
24/7 Wall St.Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
